Faculty

Jonathan Graff-Radford, M.D.

Clinical Studies

ACTC BDP: Longitudinal Follow-Up of Clinical Trial Participants for Brain Donation Rochester, Minn.
The purpose of this study is to register clinical trial participants who are interested in future brain donation.
START: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease over 18 Months (START) Rochester, Minn.
The START study is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early Alzheimer’s disease.

This study is a public-private partnership with shared leadership responsibility across the Alzheimer’s Clinical Trial Consortium (ACTC) and Cognition Therapeutics, Inc.

Participants will be enrolled across approximately 50-60 clinical sites in the United States.

AHEAD 3-45 Study Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment.
APEX: Alzheimer's Plasma Extension (APEX) Rochester, Minn.
The purpose of this study is to collect longitudinal cognitive and functional assessments and blood-based biomarker data. Also, to evaluate, characterize, and compare the longitudinal cognitive and functional data between the three groups of participants, and to compare longitudinal change across race and ethnicity, sex, and APOE status.
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD) (TRC-PAD) Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstudy.org/welcome).